硝苯地平英文介绍.doc

0934009 NIFEDIPINE HISTORY AND BACKGROUND Hypertension, elevated blood pressure indicated by systolic or diastolic pressures exceeding 140 mmHg or 90 mmHg, respectively, is becoming an increasingly important medical problem as the general population becomes older and more overweight. A recent summary of research in the area of hypertension indicates that 50 million Americans and as many as one billion people globally suffer from hypertension. More importantly, the treatment of hypertension is becoming morecomplicated as the population ages, because many patients will take drugs to treat conditions such as diabetes, rheumatoid arthritis, atherosclerosis, and so on. As such, there is a continuing evolution of treatment regimens for hypertension . In general terms, once a patient is diagnosed with hypertension, the only treatment methods are diet, exercise, and drug intervention. Although the former options can lead to some reduction in blood pressure, most patients are treated with a mono or dual drug treatment regimen. Typically, the drugs for either therapy are drawn from he diuretics, b-blockers, angiotensin- converting enzyme (ACE) inhibitors, angiotensin II antagonists, and/or calcium channel blockers. In some cases, two of the drugs are sold in a single pill. Other treatment drugs include aldosterone-receptor blockers, combined a- and b-blockers, a1-blockers, central a2-agonists, and direct vasodilators. The actual drug treatment plan depends on factors such as age, cardiac health, other health issues, and how severe the hypertension is. In addition, renin-angiotensin inhibitors are expected to become members of the treatment arsenal within the next two years. The calcium channel blockers (CCBs) are an important class of hypertension drugs incorporating three distinctive compound subtypes. Nifedipine , rst discovered in the 1960s at Bayer, remains the prototypical representative of the dihydropyridine variant of the calcium channel blockers. Verapamil and diltiazem are representatives of the other two major structural types of calcium channel blockers used for the treatment of hypertension. As mentioned before, nifedipine was the rst marketed dihydropyridine CCB. Initially, the drug indication was exclusively for angina, but the more recently developed extended release (ER) formulations are used off-label primarily for hypertension (Bayer, 2004). The extended-release tablets use a cellulose coat that extends their release time. The half- life of the ER formulation is reported as 7 h, whereas the immediate-release formulation has a half-life of 2 h (Bayer). SYNTHESIS OF NIFEDIPINE The preparation of nifedipine and other simple symmetric analogs is very straightfor- ward (Scheme 11.1). 4-Aryldihydropyridine-3,5-dicarboxylates are isolable intermediates in the well-known Hantzsch pyridine synthesis (Bossert et al., 1981; Eisner and Kuthan, 1972; Stout and Meyers, 1982). This reaction, in its most simple form, is a one-pot reaction of an aryl aldehyde, acetoacetic acid alkyl ester, and ammonia heated in reuxing methanol for a few hours. If side reactions or by-products become troublesome, a stepwise process works as well. The original preparation of nifedipine uses 2-nitrobenzaldehyde, acetoacetic acid methyl ester, methanol, and ammonia (Bossert and Vater, 1969). The mixture is heated for several hours, cooled back down, and the product is ltered off as a yellow crystalline material. CLINICAL PHARMACOLOGYNifedipine is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Nifedipine selectively inhibits calcium ion influx across the cell membrane of cardiac muscle and vascular smooth muscle without altering serum calcium concentrations.Mechanism of ActionA) AnginaThe precise mechanisms by which inhibition of calcium influx relieves angina has not been fully determined, but includes at least the following two mechanisms:1) Relaxation and Prevention of Coronary Artery SpasmNifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm, and is responsible for the effectiveness of nifedipine in vasospastic (Prinzmetals or variant) angina. Whether this effect plays any role in classical angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.2) Reduction of Oxygen UtilizationNifedipine regularly reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing the total peripheral vascular resistance (afterload) against which the heart works. This unloading of the heart reduces myocardial energy consumption and oxygen requirements, and probably accounts for the effectiveness of nifedipine in chronic stable angina.B) HypertensionThe mechanism by which nifedipine reduces arterial blood pressure involves peripheral arterial vasodilatation and the resulting reduction in peripheral vascular resistance. The increased peripheral vascular resistance that is an underlying cause of hypertension results from an increase in active tension in the vascular smooth muscle. Studies have demonstrated that the increase in active tension reflects an increase in cytosolic free calcium.Nifedipine is a peripheral arterial vasodilator which acts directly on vascular smooth muscle. The binding of nifedipine to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle results in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the influx of extracellular calcium for contraction to occur. The reduction in calcium influx by nifedipine causes arterial vasodilation and decreased peripheral vascular resistance which results in reduced arterial blood pressure. PHARMACOKINETICS AND METABOLISMNifedipine is completely absorbed after oral administration. Plasma drug concentrations rise at a gradual, controlled rate after a nifedipine extended-release tablet dose and reach a plateau at approximately six hours after the first dose. For subsequent doses, relatively constant plasma concentrations at this plateau are maintained with minimal fluctuations over the 24-hour dosing interval. About a four-fold higher fluctuation index (ratio of peak to trough plasma concentration) was observed with the conventional immediate-release nifedipine capsule at t.i.d. dosing than with once daily nifedipine extended-release tablet. At steady-state the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules. Administration of the nifedipine extended-release tablet in the presence of food slightly alters the early rate of drug absorption, but does not influence the extent of drug bioavailability. Markedly reduced GI retention time over prolonged periods (i.e., short bowel syndrome), however, may influence the pharmacokinetic profile of the drug which could potentially result in lower plasma concentrations. Pharmacokinetics of nifedipine extended-release tablets are linear over the dose range of 30 to 180 mg in that plasma drug concentrations are proportional to dose administered. There was no evidence of dose dumping either in the presence or absence of food for over 150 subjects in pharmacokinetic studies.Nifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The elimination half-life of nifedipine is approximately two hours. Only trac